Impact of MIC Range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the Ceftolozane In Vivo Pharmacokinetic/Pharmacodynamic Target

被引：50

作者：

Lepak, A. J.

Reda, A.

Marchillo, K.

Van Hecker, J.

Craig, W. A.

Andes, D. ^{[1
]}

机构：

[1] Univ Wisconsin, Dept Med, Madison, WI 53718 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2014年 / 58卷 / 10期

关键词：

CXA-101; FR264205; ANTIPSEUDOMONAL CEPHALOSPORIN; INFECTION MODELS; PHARMACOKINETICS; PHARMACODYNAMICS; TAZOBACTAM; VITRO; CEFTAZIDIME; EXPOSURES; RESISTANT;

D O I：

10.1128/AAC.03572-14

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Ceftolozane is a novel cephalosporin with activity against drug-resistant pathogens, including Pseudomonas aeruginosa and Streptococcus pneumoniae. The in vivo investigation reported here tested the limits of this drug against 20 P. aeruginosa and S. pneumoniae isolates across a wide MIC range and defined resistance mechanisms. The times above the MIC (T>MIC) targets for stasis and 1- and 2-log reductions were 31%, 39%, and 42% for P. aeruginosa and 18%, 24%, and 27% for S. pneumoniae, respectively. The 1-log endpoint was achieved for strains with MICs as high as 16 mu g/ml.

引用

收藏

页码：6311 / 6314

页数：4

相关论文

共 23 条

[1] Animal model pharmacokinetics and pharmacodynamics: a critical review [J].

Andes, D ;

Craig, WA .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (04) :261-268

[2] Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].

Boucher, Helen W. ;

Talbot, George H. ;

Bradley, John S. ;

Edwards, John E., Jr. ;

Gilbert, David ;

Rice, Louis B. ;

Scheld, Michael ;

Spellberg, Brad ;

Bartlett, John .

CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12

[3] In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms [J].

Bulik, Catharine C. ;

Tessier, Pamela R. ;

Keel, Rebecca A. ;

Sutherland, Christina A. ;

Nicolaua, David P. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (01) :544-549

[4] In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance [J].

Bulik, Catharine C. ;

Christensen, Henry ;

Nicolau, David P. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) :557-559

[5]

Clinical and Laboratory Standards Institute, 2007, M7A7 CLSI

[6] In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models [J].

Craig, W. A. ;

Andes, D. R. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (10) :3492-3496

[7] In Vivo Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice [J].

Craig, W. A. ;

Andes, D. R. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (04) :1577-1582

[8] INTERRELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS IN DETERMINING DOSAGE REGIMENS FOR BROAD-SPECTRUM CEPHALOSPORINS [J].

CRAIG, WA .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) :89-96

[9] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].

Craig, WA .

CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10

[10] Comparative In Vitro and In Vivo Efficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa [J].

Crandon, Jared L. ;

Schuck, Virna J. ;

Banevicius, Mary Anne ;

Beaudoin, Marie-Eve ;

Nichols, Wright W. ;

Tanudra, M. Angela ;

Nicolau, David P. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (12) :6137-6146